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ABSTRACT: BRCA1 and BRCA2 testing for heredi-
tary breast and ovarian cancer (HBOC) does not iden-
tify all pathogenic variants. Sequencing of 20 complete
genes in HBOC patients with uninformative test results
(N = 287), including noncoding and flanking sequences
of ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2,
EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH,
NBN, PALB2, PMS2, PTEN, RAD51B, STK11, TP53,
and XRCC2, identified 38,372 unique variants. We ap-
ply information theory (IT) to predict and prioritize non-
coding variants of uncertain significance in regulatory,
coding, and intronic regions based on changes in bind-
ing sites in these genes. Besides mRNA splicing, IT pro-
vides a common framework to evaluate potential affinity
changes in transcription factor (TFBSs), splicing regula-
tory (SRBSs), and RNA-binding protein (RBBSs) binding
sites following mutation. We prioritized variants affecting
the strengths of 10 splice sites (four natural, six cryptic),
148 SRBS, 36 TFBS, and 31 RBBS. Three variants were
also prioritized based on their predicted effects on mRNA
secondary (2°) structure and 17 for pseudoexon activa-
tion. Additionally, four frameshift, two in-frame deletions,
and five stop-gain mutations were identified. When com-
bined with pedigree information, complete gene sequence
analysis can focus attention on a limited set of variants in
a wide spectrum of functional mutation types for down-
stream functional and co-segregation analysis.
Hum Mutat 00:1–13, 2016. C© 2016 Wiley Periodicals, Inc.
KEY WORDS: 3′ untranslated region; breast neoplasm;
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Introduction
Currently, the lifetime risk for a woman to develop breast can-
cer (BC) is 12.3% and 1.3% in the case of ovarian cancer (OC
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[Howlander et al., 2014]). Approximately 5–10% of all BC cases are
hereditary in nature, versus 25% for OC, where relative risk (RR)
of BC or OC with one affected first degree family member is esti-
mated at 2.1 and 3.1, respectively [Stratton et al., 1998; Walsh et al.,
2011]. Two highly penetrant genes, BRCA1 and BRCA2, are associ-
ated with a large proportion of hereditary breast and ovarian cancer
(HBOC) cases. However, the estimated rate of linkage to these genes
is significantly higher than the proportion of pathogenic mutations
identified in HBOC families [Ford et al., 1998], suggesting unrec-
ognized or unidentified variants in BRCA1/2.
ClinicalBRCA1/2 testing is restricted primarily to coding regions.
Limitations on how variants can be interpreted, lack of functional
validation, and mutations in other genes contribute to uninforma-
tive results. The heritability that is not associatedwithBRCA genes is
likely due to other genetic factors rather than environmental causes,
specifically moderate- and low-risk susceptibility genes [Antoniou
and Easton, 2006]. Hollestelle et al. [2010] point out the challenges
in estimating increased risks associated with mutations in these
genes, as the disease patterns are often incompletely penetrant, and
require large pedigree studies to confidently assess pathogenicity.
Next-generation sequencing (NGS) of gene panels for large co-
horts of affected and unaffected individuals has become an increas-
ingly popular approach to confront these challenges. Numerous
HBOC gene variants have been catalogued, including cases in which
RR has been determined; however, the literature is also flooded with
variants lacking a clinical interpretation [Cassa et al., 2012]. It is
not feasible to functionally evaluate the effects all of the variant(s)
of uncertain significance (VUS) identified by NGS. Further, in silico
assessment of protein coding variants has not been entirely reliable
[Rogan and Zou, 2013; Vihinen, 2013]. Several approaches have
been developed to better assess variants from exome and genome-
wide NGS data [Duzkale et al., 2013; Kircher et al., 2014]. Never-
theless, there is an unmet need for other methods that quickly and
accurately bridge variant identification and classification.
To begin to address this problem, we sought to provide po-
tentially novel interpretations of noncoding sequence changes,
based on disruption or acquisition of interactions with proteins
that recognize nucleic acid binding sites. Information theory (IT)
based analysis predicts changes in sequence binding affinity, and
it has been applied and validated for use in the analysis of splice
sites (SSs), SRBSs [Rogan et al., 1998, 2003; Mucaki et al., 2013;
Caminsky et al., 2015] and TFBSs [Gadiraju et al., 2003]. A unified
framework based on IT requires binding genome-scale site data
devoid of consensus sequence bias [Schneider, 1997], for example,
photoactivatable-ribonucleoside-enhanced cross-linking and
C© 2016 WILEY PERIODICALS, INC.
Figure 1. Common genomic pathways among 20 HBOC genes, including risk and relevant literature. The left, top, and right circles indicate
sequenced genes that play important roles in the mismatch repair (MMR), Fanconi anemia, and DNA double-strand break repair pathways,
respectively. The bottom circle contains genes involved in cell cycle control. Genes considered to present a high risk of breast and/or ovarian
cancer when mutated are bolded, moderate-risk genes are underlined, and low-risk genes are in normal font. The estimated number of articles
listing a gene’s association with breast or ovarian cancer (based on a systematic search in PubMed [performed June 2015]) is indicated in
superscript. ∗∗MUTYH is only high risk in the case of bi-allelic mutations. ∗EPCAM is not involved in any pathways, but is associated with
hereditary nonpolyposis colorectal cancer (HNPCC) by virtue of the fact that 3′ deletions of EPCAM can cause epigenetic silencing of MSH2,
causing Lynch syndrome protein. See Supp. Table S1 for citations and further evidence supporting this gene set.
immunoprecipitation (PAR-CLIP), ChIP-Seq, and a compre-
hensive, validated set of SSs. Although these data sources are
heterogeneous, the IT models and binding site affinities derived
from them are uniformly scaled (in units of bits). Thus, binding
interactions involving disparate proteins or other recognition
molecules can be measured and directly compared.
We have described a unified IT framework for the identifica-
tion and prioritization of variants in coding and noncoding re-
gions of BRCA1, BRCA2, and five other HBOC genes (ATM, CDH1,
CHEK2, PALB2, and TP53 [Mucaki et al., in press; biorxiv preprint:
http://dx.doi.org/10.1101/031419]). This approach was applied to
a cohort of 102 individuals lacking BRCA mutations with a his-
tory of HBOC. This distinguished prioritized variants from flagged
alleles conferring small changes to regulatory protein binding site
sequences in 70.6% of cases (Mucaki et al., submitted).
In the present study, we have sequenced 13 additional genes that
have been deemed HBOC susceptibility loci (BARD1, EPCAM,
MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PMS2, PTEN,
RAD51B, STK11, and XRCC2 [Minion et al., 2015]). These genes
encode proteins with roles in DNA repair, surveillance, and cell
cycle regulation (Fig. 1; for further evidence supporting this gene
set see Supp. Table S1 [Apostolou and Fostira, 2013; Al Bakir and
Gabra, 2014]), and are associated with specific disease syndromes
that confer an increased risk of BC and OC, as well as many other
types of cancer (Supp. Table S2). High-risk genes confer >4 times in-
creased risk of BC compared to the general population. BRCA1 and
BRCA2 are estimated to increase risk 20-fold [Antoniou et al., 2003].
Pathogenic variants in other high-risk genes, CDH1, PTEN, STK11,
and TP53, are rarely seen outside of their associated syndromes and
account for <1% of hereditary BC cases [Maxwell and Domchek,
2013]. EPCAM, MLH1, MSH2, MSH6, and PMS2 have also been
proposed to harbor high-risk BC alleles, but the RR is still contro-
versial [Maxwell and Domchek, 2013]. Genes with moderate-risk
alleles, ATM, CHEK2, and PALB2, cause between a two- and four-
fold increased risk of BC [Apostolou and Fostira, 2013; Maxwell
and Domchek, 2013]. The remaining genes (BARD1, MRE11A,
MUTYH, NBN, RAD51B, and XRCC2) are newly identified and
currently associated with unknown risks for HBOC (Fig. 1).
We report NGS of hybridization-enriched, complete genic, and
surrounding regions of these genes, followed by variant analysis
in 287 consented patients from Southwestern Ontario, Canada,
with previously uninformative HBOC test results (this set of
patients is different from our submitted study, except for six
previously anonymous individuals who subsequently consented
to participate). We then reduced the set of potentially pathogenic
gene variants in each individual by prioritizing the results of
coding and IT analyses. After applying a frequency-based filter, the
IT-based framework prioritizes variants based on their predicted
effect on the recognition of sequence elements involved in mRNA
splicing, transcription and untranslated region (UTR) binding,
combined with UTR secondary structure and coding variant
analysis. Our approach integrates disparate sources of information,
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including bioinformatic analyses, likelihood ratios based on familial
segregation, allele frequencies, and published findings to prioritize
disease-associated mutation candidates.
Methods
Ethics and Patient Recruitment
Recruitment and consent of human participants was approved by
the University of Western Ontario Research Ethics Board (Protocol
103746). Patients were enrolled from January, 2014 throughMarch,
2015 at London Health Sciences Centre (LHSC). Patients met the
following criteria: male or female, aged between 25 and 75 years,
>10% risk of having an inherited mutation in a breast/OC gene,
diagnosed with BC and/or OC, and previously receiving uninfor-
mative results for a known, pathogenic BRCA1 or BRCA2 variant in
either the patient or other relatives (by protein truncation test, dena-
turing high-performance liquid chromatography, and/or multiplex
ligation-dependent probe amplification).
The median age of onset for patients (N = 287; Supp. Fig. S1)
with BC was 48 (N = 277) and 46 for OC (N = 17), and seven were
diagnosed with both BC and OC. Furthermore, 31 patients had
bilateral BC (98 patients at diagnosis; 23 developed tumors on the
opposite side after the initial occurrence), one had bilateral OC, and
13 have had recurrent BC in the same breast. There was a single case
of male BC (Supp. Table S3).
Probe Design, Sample Preparation, and Sequencing
Probes for sequence capture were designed by ab initio single
copy analysis, as described in Mucaki et al. (submitted) and Dor-
man et al. [2013]. The probes covered 1,103,029 nt across the 21
sequenced genes, including the negative control gene ATP8B1 (see
Supp. Methods for gene names, GenBank accession numbers, and
OMIM reference numbers). This set of genes was proposed for
evaluation at the evidence-based network for the Interpretation of
Germline Mutant Alleles (ENIGMA) Consortium Meeting (2013).
Other genes that have been found to bemutated inHBOC could not
be included (e.g., BRIP1, RAD50, RAD51C, and RAD51D; [Heikki-
nen et al., 2003; Seal et al., 2006; Janatova et al., 2015]).
PatientDNA extracted fromperipheral bloodwas either obtained
from the initial genetic testing at LHSC Molecular Genetics Labo-
ratory or isolated from recent samples. NGS libraries were pre-
pared using modifications to a published protocol [Gnirke et al.,
2009] described in Mucaki et al. (submitted), and all postcapture
pull-down steps were automated (Supp. Methods). An Illumina
Genome Analyzer IIx instrument in our laboratory was used for
sequencing.
Library preparation and resequencing were repeated for samples
with initial average coverage belowourminimumthreshold (<30×).
To ensure that the proper sample was resequenced, the variant call
format (VCF) files from each run were compared to all others in the
run using VCF compare (http://vcftools.sourceforge.net/). VCF files
from separate runs for the resequenced patients were concordant,
except for minor differences in variant call rates due to differences
in coverage. The aligned reads from both runs were then merged
(with BAMtools; http://sourceforge.net/projects/bamtools/).
Samples were demultiplexed and aligned using Consensus
Assessment of Sequencing and Variation [CASAVA; v1.8.2;
DePristo et al., 2011] and Complex Reads Analysis & Classifica-
tion (CRAC; v1.3.0; http://crac.gforge.inria.fr/). Aligned BAM files
were then preprocessed for variant calling with Picard (v.1.109;
http://broadinstitute.github.io/picard/) (MarkDuplicates, Addor-
ReplaceReadGroups, FixMateInformation). The Genome Analy-
sis Toolkit (GATK; v3.1; http://www.broadinstitute.org/gatk/) was
then used for variant calling using the modules “Indel realigner”
and the “Unified Genotyper.” Variants flagged by bioinformatic
analysis (see the section Variant Analysis) were also assessed by
manual inspection with the Integrative Genome Viewer v2.3 (IGV;
http://www.broadinstitute.org/igv/). Variants in this study are writ-
ten in HGVS notation, are based on cDNA sequence, and comply
with journal guidelines.
Information Models
Models for natural SSs and splicing regulatory factors (SRFs)
are described in Mucaki et al. [2013]. These models were used
to predict deleterious effects on natural splicing, the activation
of cryptic SSs, and changes in binding of splicing enhancers and
silencers. In addition, using a combination of cryptic site activa-
tion and hnRNPA1 site prediction, pseudoexon formation was also
assessed.
We previously built models for TFBSs (N = 83) using ENCODE
ChIP-seq data [ENCODE Project Consortium, 2012; Mucaki et al.,
submitted]. Due to the inclusion of the additional genes, eight addi-
tional transcription factors (TFs) were identified from the literature
and ENCODE ChIP-seq data from BC cell lines with evidence of
binding and potentially regulating these genes. However, models
for three of these TFs passed our quality control criteria (TFIIIB150
[BDP1], PBX3 and ZNF274; described in Lu et al., submitted).
Supp. Table S4 contains the full list of TFs (N = 86) and indicates
which genes exhibit evidence of promoter or other binding events.
Noise models (N = 5), reflecting motifs of interacting cofactors or
sequence-specific histone modifying events, were excluded (Supp.
Methods).
Information weight matrices, Ri(b,l), for sequences bound
by RNA-binding proteins (RBPs) were derived from fre-
quency matrices published in the Catalog of Inferred Se-
quence Binding Preferences of RNA binding protein (CISBP-
RNA; http://cisbp-rna.ccbr.utoronto.ca/) andRNA-Binding Protein
Database (BPDB; http://rbpdb.ccbr.utoronto.ca/). These Ri(b,l)s
were used to compute changes in binding affinity due to SNVs,
using conservative minimum information thresholds described
in Mucaki et al. (submitted). Finally, predicted changes in UTR
structure resulting from variants were determined using SNPfold
[http://ribosnitch.bio.unc.edu/snpfold/;Halvorsen et al., 2010]. Sig-
nificant changes in UTR structure and stability were represented
using mfold (http://unafold.rna.albany.edu/?q = mfold).
Variant Analysis
Information analysis has been used in the interpretation of vari-
ant effects on binding sites containing these changes, whether this
involves the creation or strengthening, or the abolition orweakening
of a site [Rogan et al., 1998]. This analysis was applied to all vari-
ants identified by NGS. Changes in information are directly related
to changes in thermodynamic entropy and thus binding affinity
[Rogan et al., 1998]. For example, a 1.0 bit change in information
corresponds to at least a twofold change in binding affinity. Infor-
mation theoretical analysis of SSs and SRF binding sites has been
extensively used and proven to be reliable and robust (85.2% ac-
curacy when compared to variants validated by expression studies)
[Caminsky et al., 2015].
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Information analysis was automated and thresholds for changes
were applied programmatically based on our previously validated
criteria [Rogan et al., 1998, 2003; von Kodolitsch et al., 2006; Dor-
manet al., 2014].This reducedmanual reviewofprioritizedvariants,
databases, and the literature. A minimum 1.0 bit threshold was set
for variants predicted to affect natural SSs or that activate a cryp-
tic SS by exceeding the strength of cognate natural sites. Variants
affecting splicing regulatory, transcription, and RBP binding sites
were assessedmore stringently and had aminimum threshold of 4.0
bits, i.e. 16-fold, in order to be flagged for further assessment. A
population frequency filter was also applied to variants with allele
frequencies >1% (in the NCBI Short Genetic Variations database
(dbSNP)) or >5% of our patient cohort. Such variants were elimi-
nated from further consideration.
To assess coding changes affecting predicted protein chain length
or amino acid(s) composition, we used SNPnexus (http://hsnp-
nexus.org/). Insertion/deletions (indels) and nonsense mutations
were noted, andmissense variantswere further assessedwith in silico
tools (Mutation Assessor, http://mutationassessor.org/; PolyPhen2,
http://genetics.bwh.arvard.edu/pph2/; PROVEAN/SIFT, http://
provean.jcvi.org/) by referencing the published literature and con-
sulting mutation databases (listed in Supp. Table S5; see Mucaki
et al. [submitted] for more details on variant analysis). Variants re-
mained prioritized unless there was clear evidence (co-segregation
analysis or functional assays) supporting the nonpathogenicity of
the variant.
EPCAM mutations in familial cancer are limited to 3′ deletions
causing epigenetic silencing of MSH2, and there is currently no
evidence of other types of variants that alter its mRNA transcript
or protein product [Ligtenberg et al., 2009]. Therefore, with the
exception of indels, none of the variants flagged in EPCAM were
prioritized. We chose to prioritize variants in MUTYH using the
same framework as all other genes, despite MUTYH pathogenicity
resulting from biallelic variants [Jones et al., 2002], because it is
possible that a secondMUTYHmutation remains unrecognized.
All protein truncating (nonsense and indels) as well as potentially
pathogenic splicing andmissense mutations were Sanger sequenced
for confirmation (details in Supp. Table S6).
Negative Control
Variants present in the ATP8B1 gene were used as negative con-
trols for our variant analysis framework. Initially, it was included
in the list of prioritized HBOC genes provided by ENIGMA, but
evidence for its association with HBOC is lacking in the published
literature. Furthermore, it is not a known susceptibility gene for
any type of cancer (mutations in ATP8B1 cause progressive familial
intrahepatic cholestasis [Gonzales et al., 2014]) and is infrequently
mutated in breast tumors in several studies (e.g., seeCancerGenome
Atlas Network [2012]).
Likelihood Ratios
Patients with prioritized coding and/or splicing variants, which
we consider the most likely to be pathogenic, were selected for
co-segregation analysis (N = 24) using an online tool that calculates
the likelihood of a variant being deleterious based on pedigree in-
formation (https://www.msbi.nl/cosegregation/; Mohammadi et al.
[2009]). Genotypes were assigned based on phenotype such that
family members with breast or OC at any age were assigned the
same genotype as the patient in our study (“carrier”) and fam-
ily members affected by other cancers, other diseases, or who are
disease free were assigned the “noncarrier” genotype. Because the
penetrance parameters cannot be altered from the settings given for
BRCA1 or BRCA2, the BRCA2 option was selected for patients with
prioritized variants in non-BRCA genes. Penetrance in BRCA2 is
known to be lower than BRCA1 values [Mohammadi et al., 2009].
Current evidence suggests that mutations in non-BRCA genes may
be less penetrant than those in the BRCA genes [Apostolou and
Fostira, 2013]; however, the penetrance of many of these variants
remains unknown (Supp. Methods).
Results
Variant Analysis
We identified 38,372 unique variants among 287 patients (26,636
intronic, 7,287 intergenic, and 714 coding), on average 1,975 vari-
ants per patient, before any filtering criteria were applied. The ex-
tensive span of sequences captured in this study, that is, complete
genes and flanking regions, constrained the genomic density and
sequence coverage that could be achieved; this precluded accurate
copy number estimation based solely on read counts.
Natural site variants
The Shannon Human Splicing Mutation Pipeline (http://www.
mutationforecaster.com; Shirley et al. [2013]) was used to predict
the effect of the 14,458 variants that could potentially affect splic-
ing, of which 244 reduced natural SS strength. Further stringent
filtering of the natural SS based on information content changes
and allele frequency resulted in seven flagged variants (Supp. Table
S7). Henceforth, allele frequency of known variants can be found in
their associated supplemental table (where available).
Four of these variants were prioritized (Table 1). A novel syn-
onymous variant in exon 2 of RAD51B, c.84G>A (p.Gln28 = ), is
predicted to increase exon skipping by weakening the natural splice
donor (Ri,final = 5.2 bits, Ri = –3.0 bits). A known ATM variant,
c.6198+1G>A (8-1D.9-1B [Stankovic et al., 1998]), abolishes the
natural donor SS of constitutively spliced exon 42 (Ri,final = –13.7
bits,Ri = –18.6 bits). There is no evidence in public databases for
appreciable alternative splicing of this exon in normal breast tissues.
The variant will either lead to exon skipping or activation of a preex-
isting cryptic site (Fig. 2). An ataxia-telangiectasia patient with this
variant exhibited low expression, protein truncation, and abolished
kinase activity of ATM [Reiman et al., 2011]. MLH1 c.306+4A>G
causes increased exon skipping (and a decrease in wild-type exon
relative expression) due to the weakening (Ri,final = 6.0 bits, Ri =
–2.6 bits) of the exon 3 natural donor. Tournier et al. [2008] assessed
this variant using an ex vivo splicing assay and observed cryptic site
activation and exon 3 skipping.MRE11A c.2070+2A>T is indicated
in ClinVar as likely pathogenic and abolishes the natural donor site
of exon 19 (Ri,final = –11.0 bits, Ri = –18.6 bits), while strengthen-
ing a cryptic site 5 nt upstream of the splice junction (Ri,final = 8.1
bits, Ri = 0.6 bits). Either cryptic SS activation or complete exon
skipping are predicted.
The BRCA2 variant c.68-7T>A was not prioritized, as its
pathogenicity has not been proven. While there is evidence that
this variant induces (in-frame) exon skipping [The´ry et al., 2011], it
did not segregate with disease in HBOC pedigrees, where abnormal
splicing was not seen [Santos et al., 2014]. The ATM variant c.1066-
6T>G, previously reported in Mucaki et al. (submitted), was also
not prioritized as the variant does not correlate with BC risk [Ding
et al., 2011].
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Table 1. Prioritized Variants Predicted by IT to Affect Natural and Cryptic Splicing
Information change
Gene Variant rsID (dbSBP142) allele frequency (%)c Ri,initial (bits) Ri,final (bits) Ri (bits) Consequence
ATM NM 000051.3:c.6198+1G>A
[Stankovic et al., 1998; Reiman
et al., 2011]
– 4.9 –13.7 –18.6 Abolished naturald,g
MRE11A NM 005591.3:c.2070+2A>Ta – 7.6 –11 –18.6 Abolished naturald,g
MLH1 NM 000249.2:c.306+4A>Ga
[Tournier et al., 2008]
rs267607733 8.6 6 –2.6 Weakened naturale
RAD51B NM 002877.4:c.84G>Aa
p.Gln28=
Novel 8.2 5.2 –3 Weakened naturald
BARD1 NM 000465.2:c.1454C>Ta
p.Ala485Val
Novel –2.7 4.4 7.1 Created cryptice
BRCA1 NM 007294.2:c.5074+107C>T rs373676607 –1.3 5.7 7 Created crypticf ,h
CDH1 NM 004360.3:c.1223C>Ga
p.Ala408Gly [Schrader et al.
2011]
Novel –0.6 4.3 4.9 Created cryptice
RAD51B NM 002877.4:c.958-29A>Tb rs34436700 0.78 2.2 4.4 2.2 Strengthened crypticf
STK11 NM 000455.4:c.375-194GT>AC rs35113943 17.61 rs117211142 0.80 7.5 8.8 1.3 Strengthened crypticf
XRCC2 NM 005431.1:c.122-154G>T Novel 8.1 10 1.9 Strengthened crypticc
aConfirmed by Sanger sequencing.
bAmbiguous Sanger sequencing results.
cIf available
dExon skipping
eExon truncation
fIntron retention
gUse of alternate isoform
hReduced expression of natural isoform.
Activation of cryptic splicing
The Shannon Pipeline identified 9,480 variants that increased the
strength of at least one cryptic site, of which nine met or exceeded
the defined thresholds for information change. Six of these were
prioritized (Table 1). A novel BARD1 variant in exon 6 (c.1454C>T;
p.Ala485Val) creates a donor SS (Ri,final = 4.4 bits, Ri = 7.1 bits),
whichwould produce a 58nt frameshifted exon if activated. Thenat-
ural donor SSof exon6, 116nt downstreamof the variant, is stronger
(5.5 bits), but the Automated Splice Site and Exon Definition Anal-
ysis (ASSEDA, http://mutationforecaster.com) server predicts equal
levels of expression of both natural and cryptic exons. ABRCA1mu-
tation 5074+107C>T downstream of exon 16 is predicted to extend
the exon by 105 nt and be slightly more abundant than the natu-
ral exon (Ri,total of 8.6 and 8.1 bits, respectively). CDH1 c.1223C>G
(p.Ala408Gly), previously reported in a BRCA-negative lobular BC
patient with no family history of gastric cancer [Schrader et al.,
2011], creates a cryptic donor site (Ri,final = 4.3 bits, Ri = 4.9 bits)
in exon 9, 97 nt downstream of the natural acceptor. While residual
splicing of the normal exon is still expected, the cryptic is predicted
to become the predominant splice form (twice as abundant).
STK11 c.375-194GT>AC (rs35113943 and rs117211142) and the
novel XRCC2 c.122-154G>T both strengthen strong preexisting
cryptic sites exceeding the Ri,total values of their respective natu-
ral exons. Finally, a known RAD51B variant 29 nt upstream of exon
10: c.958-29A>T strengthens a cryptic acceptor site (Ri,final = 4.4
bits, Ri = 2.2 bits) that, if activated, would produce a transcript
retaining 21 intronic nucleotides.
The remaining cryptic site variants (Supp. Table S7) were not
prioritized. The novel BRCA2 c.7618-269 7618-260del10 variant
is predicted to create a cryptic site with an exon having a lower
Ri,total value (5.2 bits) than the natural exon (6.6 bits). PMS2
c.1688G>T (p.Arg563Leu; rs63750668; three patients) does not seg-
regate with disease. Drost et al. [2013] demonstrated that this vari-
ant does not impair DNA repair activity. Finally, RAD51B c.728A>G
(p.Lys243Arg; rs34594234; 7 patients) predicts an increase in the
abundance of the cryptic exon; however, the natural exon remains
the predominant isoform.
Pseudoexon activation
Pseudoexons arise from creation or strengthening of an intronic
cryptic SS in close proximity to another intron site of opposite po-
larity. Our analysis detected 623 variants with such intronic cryptic
sites, of which 17 were prioritized (among nine genes), occurring
within 250 nt of a preexisting site of opposite polarity, with an
hnRNPA1 site within 5 nt of the acceptor of the predicted pseu-
doexon (Supp. Table S8). Three are novel (BRCA2 c.7007+824C>T,
BRCA2 c.8332-1130G>T, andPTEN c.802-796C>A)and the remain-
der were present in dbSNP. Seven of these variants (BARD1 c.1315-
168C>T, BRCA2 c.631+271A>G, MLH1 c.1559-1732A>T, MRE11A
c.1783+2259A>G, MSH6 c.260+1758G>A, PTEN c.79+4780C>T,
and RAD51B c.1037-1012C>A), although rare, occur in multiple
patients, andonepatient hadpredicted pseudoexons in bothBARD1
and RAD51B.
SRF binding
Variants within exons or within 500 nt of a natural SS (N = 9,998)
were assessed for their potential effect on SRF binding sites (SRF-
BSs). Initially 216 unique variants were flagged (Supp. Table S9),
but after considering each in the context of the SRF function and
location within the gene [Caminsky et al., 2015], we prioritized
148, of which 57 are novel. Some prioritized variants affect distant
SRFs that may activate cryptic sites, but were not predicted to affect
natural splicing. Of the 88 suitable prioritized variants for which
exon definition analysis was performed (where initial Ri,total of the
exon > SRF gap surprisal value), 55 were predicted to induce or
contribute to increased exon skipping. For example, an uncommon
ATM missense variant within exon 41, c.6067G>A (p.Gly2023Arg;
rs11212587), strengthens an hnRNPA1 site (Ri,final = 5.2 bits,
HUMANMUTATION, Vol. 00, No. 0, 1–13, 2016 5
Figure 2. Predicted isoforms and relative abundance as a consequence of ATM natural splice variant c.6198+1G>A. (A) Intronic ATM variant
c.6198+1G>A abolishes the natural donor of exon 42 (Ri,initial = 4.9 bits, Ri = –18.6 bits), and would either result in exon skipping (causing a
frame-shift; isoform 15 after mutation), or possibly activate a downstream cryptic site (isoform 1 maintains reading frame, isoform 2 would not).
(B) The peaks in plot display the predicted abundance (Y-axis) of a splice isoform (X-axis) relative to another predicted isoform (Z-axis). In the
wild-type mRNA, the natural exon (isoform 15) has the highest predicted relative abundance. Before mutation, it is predicted to be approximately
fivefold stronger than isoform 1 and 2. (C) After mutation, isoform 1 and 2 is now > 100,000-fold stronger than isoform 15 (abolished wild-type exon).
Isoform 2 to be slightly less abundant than 1.
Ri = 4.7 bits) 30 nt from the natural donor, and is predicted
to induce exon 41 skipping (Ri,total = –9.5 bits).
TF binding
To assess potential changes to TFBSs, variants occurring from 10
kb upstream of the start of transcription through the end of the first
intron were analyzed by IT, flagging 88 (of 4,530 identified; Supp.
Table S10). Considering the gene context of each TFBS and extent of
information change,weprioritized 36 variants. The following exam-
ple illustrates the rationale for highlighting these variants: BRCA1
c.-19-433A>G abolishes a binding site for HSF 1 (Ri,initial = 5.5 bits,
Ri = –7.8 bits). While HSF 1 is known to be a transcriptional acti-
vator associated with poor BC prognosis [Santagata et al., 2011], the
specific effect of reduced HSF 1 binding to BRCA1 has not been es-
tablished. Similarly,MLH1 c.-4285T>C (rs115211110; five patients)
significantly weakens a C/EBPβ site (Ri,initial = 10.1 bits, Ri = –6.3
bits), a TF that has been shown to play a role in BC development and
progression [Zahnow, 2009]. Another MLH1 variant, c.-6585T>C
(novel), greatly decreases the binding strength (Ri,initial = 12.5 bits,
Ri = –10.8 bits) of the NF-κB p65 subunit, which is activated
in ER-negative breast tumors [Biswas et al., 2004]. Two prioritized
variants (PMS2 c.-9059G>C and XRCC2 c.-163C>A) weaken PAX5
binding sites, a TF which when overexpressed can result in mam-
mary carcinoma cells regaining epithelial cell characteristics [Vidal
et al., 2010].
Alterations to mRNA structure
A total of 1,355 variants were identified in the 5′ and 3′ UTRs
of the patients. Analysis of these variants with SNPfold flagged
three unique variants (P < 0.05) in BRCA1, BARD1, and XRCC2
(Table 2). The predicted mRNA 2° structures of the reference and
variant sequences are shown in Figure 3 (generated with mfold).
The BRCA1 variant occurs in the 3′ UTR of all known transcript
isoforms (NM 007294.3:c.∗1332T>C; rs8176320; 3 patients). The
most likely inferred structure consisting of a short arm and a larger
stem loop is destabilized when the variant nucleotide is present
(Fig. 3A and B). The BARD1 variant falls within the 5′ UTR of
a rare isoform (XM 005246728.1:c.-53G>T; rs143914387; five pa-
tients) and is within the coding region of a more common tran-
script (NM 000465.2:c.33G>T; p.Gln11His). While the top ranked
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Table 2. Variants Predicted by SNPfold to Significantly Affect UTR Structure
Gene Variant UTR position rsID (dbSNP142) allele frequency (%)a Rank P-value
BARD1 XM 005246728.1:c.-53G>T (c.33G>T p.Gln11His) 5′UTR rs1439143870.04 6/600 0.01
BRCA1 NM 007294.3:c.∗1332T>C NM 007299.3:c.∗1438T>C 3′UTR rs81763200.42 13/450 0.03
XRCC2 NM 005431.1:c.-76C>T 5′UTR rs5475387310.08 3/300 0.01
aIf known.
Figure 3. Predicted RNA structure change due to variants flagged by SNPfold using mfold. Wild-type (A, C, and E) and variant (B, D, and
F) structures are displayed. The variant nucleotide is marked with an arrow. (A) Predicted wild-type structure of BRCA1 3′ UTR surrounding
c.∗1332G>A. (B) BRCA1 3′ UTR structure due to c.∗1332A variant, extending arm length while reducing hairpin size. (C) BARD1 5′ UTR structure
of rare isoform (XM_005246728.1:c.-53G>T). Two overlapping preexisting RBP sites (SRSF7 [outer box] and SRSF2 [inner box]) are predicted and
either could occupy this location if accessible. (D) 2° BARD1 5′ UTR structure of the region predicted only with sequence containing the c.-53T
mutation. The primary predicted c.-53T structure is identical to wild type (with one disrupted C-G bond leading to a 4.1 kcal/mol lower G). The
variant both weakens and abolishes the preexisting SRSF7 and SRSF2 sites, respectively. (E) XRCC2 structure within common 5′ UTR surrounding
c.-76C>T variant. (F) XRCC2 5′ UTR structure predicted from c.-76T sequence, containing a hairpin not found in wild type. This hairpin may allow
for the binding of previously inaccessible nucleotides including the altered nucleotide.
isoform followingmutation is similar to the wild-type structure, the
second-ranked isoform (G= +1.88kcal/mol) is distinctly different,
creating a loop in a long double-stranded structure (Fig. 3C and D).
TheXRCC2 variant is within its common 5′ UTR (NM 005431.1:c.-
76C>T) and is located 11 nt downstream from the 5′ end of the
mRNA. The variant nucleotide disrupts a potential GC base pair,
leading to a large stem-loop that could allow access for binding of
several RBPs (Fig. 3E and F). The variant simultaneously strength-
ens PUM2 (Ri,initial = 2.8 bits, Ri = 4.4 bits, positions 11–17) and
RBM28 sites (Ri,initial = 4.0,Ri = 3.6 bits, positions 10–13); however,
there is a stronger NCL site (8.3 bits, positions 20–31) in the area
that is not affected and may compete for binding.
RBP binding
Using IT models of 76 RBBSs, 33 UTR variants were prioritized
(Supp. Table S11) from the initial list of 1,367 UTR variants. In-
terestingly, one of the three variants that destabilized the mRNA
was also flagged using our RBP scan. The BARD1 c.-53A>C variant
weakens a predicted 8.3 bit SRSF7 site (Ri = –3.0 bits) while si-
multaneously abolishing a predicted 9.7 bit SRSF2 site (Ri = –29.7
bits) (Fig. 3C and D).
Exonic Protein-Altering Variants
Protein truncating
Of the 714 identified coding variants, six were indels, each
of which were found in a single patient, and two preserved the
reading frame. Two indels were novel (BRCA1:c.3550 3551insA
[p.Gly1184Glufs] and CDH1:c.30 32delGCT [p.Leu11del]). Previ-
ously reported indels were detected in CHEK2 and PALB2. In addi-
tion, five nonsense mutations, which have been previously reported
by others, were found in six different patients (Table 3; details in
Supp. Table S12).
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Table 3. Variants Resulting in Premature Protein Truncation
Gene Exon Variant
rsID (dbSNP142)
allele frequency (%)a Details
Frameshift insertions/deletions
BRCA1 10 of 23 NM 007294.2:c.3550 3551insAb p.Gly1184Glufs Novel STOP at p.1187 676 AA short
PALB2 4 of 13 NM 024675.3:c.757 758delCTc p.Leu253Ilefs rs180177092 STOP at p.255 932 AA short
PALB2 9 of 13 NM 024675.3:c.2920 2921delAAc p.Lys974Glufs rs180177126 STOP at p.979 208AA short
Insertions/deletions with conserved reading frame
CDH1 1 of 16 NM 004360.3:c.30 32delGCTd p.Leu11del Novel Loss of one AA frame and AA
sequence conserved
CHEK2 4 of 14 NM 007194.3:c.483 485delAGAc p.Glu161del – Loss of one AA frame and AA
sequence conserved
Stop codons
ATM 13 of 63 NM 000051.3:c.1924G>Tc p.Glu642Ter – 2415 AA short
ATM 62 of 63 NM 000051.3:c.8977C>Tc p.Arg2993Ter – 64 AA short
BRCA1 23 of 23 NM 007294.2:c.5503C>Tb p.Arg1835Ter rs41293465 28 AA short
PALB2 13 of 13 NM 024675.3: c.3549C>Gc p.Tyr1183Ter rs118203998 4 AA short
aIf known.
bNot confirmed through Sanger sequencing.
cConfirmed by Sanger sequencing.
dAmbiguous Sanger sequencing results.
AA: amino acid.
Missense variants
Of the 155 unique missense variants (Supp. Table S13), 119 were
prioritized by consulting published literature, disease- and gene-
specific databases. All are of unknown clinical significance and 21
have not been previously reported.
Missense variants that have been previously described as
detrimental include the ATM variant c.7271T>G (p.Val2424Gly;
rs28904921; two patients), which replaces a hydrophobic residue by
glycine in the conserved FATdomain and confers a ninefold increase
(95% CI) in BC risk [Goldgar et al., 2011]. Functional studies, as-
sessingATMkinase activity in vitrowithTP53 as a substrate, showed
that cell lines heterozygous for the mutation had less than 10% of
wild-type kinase activity, such that this variant is expected to act in
a dominant-negative manner [Chenevix-Trench et al., 2002]. The
CHEK2 variant c.433C>T (p.Arg145Trp; rs137853007; one patient)
results in rapid degradation of the mutant protein [Lee et al., 2001].
Finally, the PMS2 variant c.2T>C (p.Met1Thr) is listed in ClinVar as
pathogenic and would be expected to abrogate correct initiation of
translation. This variant has not been reported in BC families, but
is associated with colorectal cancer (CRC) [Senter et al., 2008].
Variant Prioritization
We prioritized an average of 18.2 variants in each gene, ranging
from seven (XRCC2) to 61 (ATM), an average of 0.41 variants/kb,
and an average of 0.65 variants/patient (Table 4). ATM had the sec-
ond greatest gene probe coverage (103,511 nt captured), the highest
number of unique prioritized variants, andwas among the top genes
for number of prioritized variants per kilobase (0.59).
In total, our framework allowed for the prioritization of 346
unique variants in 246 patients, such that 85.7% of tested patients
(N = 287) had at least one prioritized variant.Most patients (84.7%)
harbored fewer than four prioritized variants. The distribution of
patientswithprioritizedvariantswas similar across eligibility groups
(Table 5). Although Class 5 (91.1% of patients with prioritized vari-
ants) and Class 8 (100% with prioritized variants, with a single
patient in this category) deviated to a greater extent from the mean
variants/category, these differences were not significant, χ 2 (4, N =
246) = 0.98, p > 0.90. The distribution of prioritized variants among
mutation types is nine protein truncating, 28 mRNA splicing, 34
Table 4. Comparing Counts of Prioritized Variants
Gene
Unique
prioritized
variants
Unique
patients
Gene probe
coverage
(nt)
Prioritized
variants/
patient
Prioritized
variants/kb
ATM 61 102 103,511 0.60 0.59
ATP8B1 21 37 94,793 0.57 0.22
BARD1 17 46 73,735 0.37 0.23
BRCA1 19 24 52,075 0.79 0.36
BRCA2 24 28 73,332 0.86 0.33
CDH1 21 32 61,312 0.66 0.34
CHEK2 12 13 28,372 0.92 0.42
MLH1 18 25 50,553 0.72 0.36
MRE11A 17 31 64,713 0.55 0.26
MSH2 18 17 112,437 1.06 0.16
MSH6 19 23 25,216 0.83 0.75
MUTYH 8 16 21,439 0.50 0.37
NBN 11 21 57,067 0.52 0.19
PALB2 26 46 25,319 0.57 1.03
PMS2a 8 15 11,726 0.53 0.68
PTENb 15 23 86,059 0.65 0.17
RAD51Bc 22 47 62,465 0.47 0.35
STK11 12 20 28,373 0.60 0.42
TP53 11 30 23,544 0.37 0.47
XRCC2 7 10 19,942 0.70 0.35
aHomologous to other genomic regions, thus fewer probes designed within gene.
bPTEN has pseudogene PTENP1, thus fewer probes covering exonic regions.
cProbes limited to 1,000 nt surrounding all exons, and 10,000 nt up- and downstream
of gene.
affecting RBBS and/or UTR structure, 36 affecting TFBS, 119 mis-
sense, and 149 affecting SRFBS, of which 29 were prioritized into
multiple categories (Supp. Tables S14 and S15 show this information
by gene and patient, respectively).
All prioritized protein-truncating (N = 10), and selected splicing
(N = 7) and missense (N = 5) variants were verified by bidirectional
Sanger sequencing as they weremore likely to be pathogenic (taking
into account available published studies). Of the protein-truncating
variants, four nonsense, one indel with a conserved reading frame,
and two frameshifts were confirmed (Table 3). Six splicing vari-
ants and all missense were confirmed (Table 1 and Supp. Table
S13). An additional 145 prioritized variants, including 88 noncod-
ing variants, were confirmed upon resequencing of patient gDNA.
Of the 57 resequenced coding variants, 13 were prioritized for their
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Table 5. Distribution of Recruited Patients among Eligibility Groups
Eligibility groupa
Number of
patients within
eligibility group
Number of patients
with prioritized
variants
Breast cancer <60 years, and a first- or second-degree relative with ovarian cancer or male breast cancer (5) 68 62
Breast and ovarian cancer in the same individual, or bilateral breast cancer with the first case <50 years (6) 37 32
Two cases of ovarian cancer, both <50 years, in first- or second-degree relatives (7) 72 59
Two cases of ovarian cancer, any age, in first- or second-degree relatives (8) 1 1
Three or more cases of breast or ovarian cancer at any age (10) 109 92
287 246
The risk categories for individuals eligible for screening for a genetic susceptibility to breast or ovarian cancers are determined by the Ontario Ministry of Health and Long
Term-Care Referral Criteria for Genetic Counseling.
aNumbers in parentheses correspond to eligibility group designation.
noncoding effects (12 SRFBS, two cryptic site strengthening; one
variant prioritized for both). These variants can be found in Supp.
Table S15 (where “coverage” column contains two ormore coverage
values).
Negative control
ATP8B1 was sequenced and analyzed in all patients as a negative
control (Supp.Table S16).Weprioritized21ATP8B1variantswithan
average of 0.22 variants/kb and 0.57 variants/patient. This is lower
than the prioritization rate for many of the documented HBOC
genes. This result illustrates that the proposed method represents a
screening rather than a diagnostic approach, as some variants may
be incorrectly prioritized.
Pedigree Analysis
Pathogenic BRCA2 variants within a region of exon 11 have
been associated with a high incidence of OC. We therefore veri-
fied whether there were a high number of OC cases in the families of
patients prioritized with exon 11 BRCA2 variants (N = 3). The fam-
ily of the patient with BRCA2 variant c.4828G>A (p.Val1610Met;
diagnosed with BC at 65) has three reported cases of BC/OC, one
of which is OC (diagnosed at 74), two degrees of separation from
the proband. The patient with BRCA2:c.6317T>C (p.Leu2106Pro;
diagnosed with BC at 52) has three other affected family members,
two with OC and one with BC. Finally, four patients found to have
the BRCA2 variant c.5199C>T (p.Ser1733 = ) do not have any family
members with reported cases of OC.
We also selected patients with prioritized mismatch repair vari-
ants (N = 8 in 10 patients) to assess the incidence of reported
CRC cases in these families. Notably, the patient with mutation
MSH2:c.1748A>G (p.Asn583Ser) had five relatives with CRC. A
similar analysis of prioritized CDH1 variants did not reveal any
patients with a family history of gastric cancer.
LR Analyses
We carried out co-segregation analysis of 25 patients with pri-
oritized pathogenic variants (four nonsense, four frameshift, two
in-frame deletions, six missense, four natural splicing, and six cryp-
tic splicing; including a patient who exhibited prioritized natural
and cryptic SS variants). We compared these findings with those
from patients (N = 25) harboring moderate-priority variants (vari-
ants prioritized through IT analysis only) and those in whom no
variants were flagged or prioritized (N = 14). In instances where
disease alleles could be transmitted through either founder parent,
the lineage with the highest likelihood ratio (LR) was reported.
For patients with likely pathogenic variants, the LRs ranged from
0.00 to 70.96 (Table 6 and Supp. Table S17). Disease co-segregation
was supported (LR > 1.0) in 18 patients, and the remainder were
either neutral (LR < 1.0 [Mohammadi et al., 2009]) or could not
be analyzed either due to missing pedigree information or limited
numbers of affected individuals in a family. Patient 10–6F (PALB2:
c.757 758delCT) exhibited the highest likelihood (LR = 70.96). Pri-
oritized variants with neutral evidence include a variant that abol-
ishes a natural SS in MRE11A, c.2070+2T>A (LR = 0.03), and an
in-frame deletion c.483 485delAGA in CHEK2 (LR = 0.00).
Discussion
Rare noncoding and/or non-truncating mutations can confer an
increased risk of disease in BC [Tavtigian et al., 2009]. This study
determined both coding and noncoding sequences of 20 HBOC-
related genes, with the goal of discovering and prioritizing rare vari-
ants with potential effects on gene expression. This work emphasizes
results from the analysis of noncoding variants, which are abundant
in these genes, yet have been underrepresented in previous HBOC
mutation analyses. Nevertheless, alterations to mRNA binding sites
in BRCA, and lower risk or rare HBOC genes, have been shown
to contribute to HBOC (exonic splicing enhancers (ESEs) in ATM
[Heikkinen et al., 2005], BARD1 [Ratajska et al., 2011], and BRCA
genes [Gochhait et al., 2007; Sanz et al., 2010]). We prioritized 346
unique variants that were predicted to result in four nonsense, three
frameshift, two indels with preserved reading frame, 119 missense,
four natural splicing, six cryptic splicing, 17 pseudoexon activating,
148 SRFBS, 36 TFBS, three UTR structure, and 31 RBBS mutations
(Supp. Table S14). Among these variants, 101 were novel (see Supp.
Table S18 for references to previously identified variants). Com-
pared to our initial seven-gene panel (Mucaki et al., submitted), the
inclusion of the additional genes in this study prioritized at least one
variant in 15% additional patients (increased from 70.6 to 85.7%).
The BRCA genes harbor the majority of known germline
pathogenic variants for HBOC families [Chong et al., 2014]. How-
ever, a large proportion of the potentially pathogenic variants identi-
fied in our study were detected in ATM, PALB2, andCHEK2, which,
although of lower penetrance, were enriched because the eligibility
criteria excluded known BRCA1 and BRCA2 carriers. BRCA1 and
BRCA2 variants were nevertheless prioritized in some individuals.
We also had expected intragenic clustering of some BRCA coding
variants [Mucaki et al., 2011]. For example, pathogenic variants oc-
curring within exon 11 of BRCA2 are known to be associated with
higher rates ofOC in their families [Lubinski et al., 2004].We identi-
fied three variants in exon 11; however, there was no evidence of OC
in these families. Overall, ATM and PALB2 had the highest number
of prioritized variants (61 and 26, respectively). However, only 12
variants were prioritized in CHEK2; potentially pathogenic variants
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Table 6. LR Values for Patients with Prioritized Truncating, Splicing, and Selected Missense Variants
Variant
Genesa mRNA Protein Category UWO ID LR
ATM c.1924G>T p.Glu642Ter Nonsense 10-2F 7.46MGM,9.61MGF
c.6198+1G>A – Natural splicing 8-1D.9-1B 1.00
c.7271T>G p.Val2424Gly Missense 10-1F 1.44
12-1D 1.96P
c.8977C>T p.Arg2993Ter Nonsense 12-4G.13-5D 5.30P
BARD1 c.1454C>T p.Ala485Val Cryptic splicing 8-1D.9-1B 1.00
BRCA1 c.3550 3551insA p.Gly1184Glufs Frameshift indel 11-6H 3.36P
c.5503C>T p.Arg1835Ter Nonsense 8-5D.9-5D 41.99
BRCA2 c.10095delCins11 p.Ser3366Asnfs Frameshift indel 15-4E 3.71
CDH1 c.30 32delGCT p.Leu11del Inframe deletion 10-4A 1.00
c.1223C>G p.Ala408Gly Cryptic splicing 15-3G 2.14
CHEK2 c.470T>C p.Ile157Thr Missense 12-2G 2.86
15-5G 19.44P
c.433C>T p.Arg145Trp Missense 4-3C.5-4G.14-4A 3.48
PALB2 c.3549C>G p.Tyr1183Ter Nonsense 15-1E 1.78
c.757 758delCT p.Leu253Ilefs Frameshift indel 10-6F 70.96
c.2920 2921delAA p.Lys974Glufs Frameshift indel 8-3A.9-3A 5.03
PMS2 c.2T>C p.Met1Thr Missense 11-4H 16.53P
RAD51B c.84G>A p .Gln28= Leaky splicing 8-1H.9-1E 3.51P
c.958-29A>T – Cryptic splicing 10-4B 7.44P
STK11 c.375-194GT>AC – Cryptic splicing 10-5A 2.67M
LR values in favor of neutrality are not shown.
aRefSeq accessions: ATM (NM_000051.3), BARD1 (NM_000465.2), BRCA1 (NM_007294.2), BRCA2 (NM_000059.3), CDH1 (NM_004360.3), CHEK2 (NM_007194.3), PALB2
(NM_024675.3), PMS2 (NM_000535.5), RAD51B (NM_002877.4), STK11 (NM_000455.4).
P, paternal; M, maternal; MGF, maternal grandfather; MGM, maternal grandmother.
may have been underrepresented during sequence alignment as a
consequence of the known paralogy with CHEK2P2.
Fewer TP53, STK11, and PTEN variants were prioritized, as
pathogenic variants in these genes tend to be infrequent in pa-
tients who do not fulfill the clinical criteria for their associated
syndromes (Li-Fraumeni syndrome, Peutz-Jeghers syndrome, and
Cowden syndrome, respectively [Hollestelle et al., 2010]), although
they have been indicated as near moderate to high-risk genes in
BC [Easton et al., 2015]. This underrepresentation of prioritized
variants may be supported by the negative Residual Variation Intol-
erance Scores (RVIS) for these genes [Petrovski et al., 2013], which
are likely indicative of purifying selection. Although the density of
prioritized variants in these genes is below average (18.2 per gene),
the total number was nonetheless important (TP53 = 11, STK11 =
12, PTEN = 15).
The fundamental difference between IT and other approaches
such as combined annotation-dependent depletion [CADD;Kircher
et al., 2014] is that IT depends only on positive experimental data
from the same or closely related species. CADD does not appear
to account for unobserved reversions or other hidden mutations
[e.g. perform a Jukes–Cantor correction; Jukes and Cantor, 1969],
nor are the effects of these simulated. Furthermore, the CADD
scoring system is ad hoc, which contrasts with strong theoretical
basis on the IT approach (Rogan and Schneider, 1995) in which
information changes in bits represent a formally proven relationship
to thermodynamic stability, and therefore can be used to measure
binding affinity. Thismakes it different from other unitlessmethods
with unknowndistributions, inwhich differences in binding affinity
cannot be accurately extrapolated from derived scores.
We compared the frequency of all prioritized variants in our pa-
tient cohort to the population allele frequencies [1000 Genomes
Project, Phase 3; http://www.1000genomes.org; 1000 Genomes
Project Consortium, 2012] to determine if variants more common
in our cohort might be suggestive of HBOC association. Three vari-
ants in at least five HBOC patients are present at a much lower
frequency in the general population than in our HBOC popula-
tion. NBN c.∗2129G>T, present in 4.18% of study cohort, is con-
siderably rarer globally (0.38% in 1000 Genomes; <0.1% in other
populations). Similarly, the RAD51B c.-3077G>T variant (2.09%)
is rare in the general population (0.08%). Interestingly, BARD1
c.33G>T (1.74% of study cohort) has only been reported in the
American and European populations in 1000 Genomes (0.29%
and 0.20%, respectively) and only Europeans in the Exome Variant
Server (0.24%; http://evs.gs.washington.edu/EVS/). In Southwest-
ernOntario, individuals areoftenofAmericanorEuropeanancestry.
The variant was found to be more common in the Exome Aggrega-
tion Consortium (ExAC; http://exac.broadinstitute.org/) in 1.17%
tested Finnish population (0.41% in their non-Finnish European
cohort), though no alleles were found in the Finnish populations
in 1000 Genomes (N = 99). Therefore, the allele frequency of this
BARD1 variant in ourHBOCpopulationmay simply be enriched in
a founder subset of general populations. While we cannot rule out
skewing of these allele frequencies due to population stratification,
our findings suggest that gene expression levels could be impacted
by these variants.
We applied subpopulation allele frequency analysis for all of our
prioritized variants. Supp. Table S19 lists the 49 variants that have
allele frequencies >1% in various subpopulations (based ondbSNP).
Allele frequencieswere as high as 4.2% for theBRCA2 c.-40+192C>T
(8-1G.9-1C), predicted to affect TF binding, in the East Asian sub-
population. Without additional information on patient ethnicities,
it is not possible to eliminate prioritized variants that are common
in specific subpopulations.
Co-segregation analysis is recommended by the American Col-
lege of Medical Genetics and Genomics for variant classification
[Richards et al., 2015]. Among patients with likely pathogenic,
highly penetrant mutations in our cohort (N = 24), some variants
had LR values consistent with causality, whereas others provided
little evidence to support co-segregation among family members
(Table 6 and Supp. Table S17). An important caveat, however, was
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that the use of BRCA2 penetrance values in non-BRCA genes may
have resulted in underestimates of LR values.
In order to evaluate the application of co-segregation analysis in
the contextof this study,wechose toperformthis analysis onpatients
withmoderate priority variants (i.e., variants affecting binding sites)
and patients with no flagged or prioritized variants (N = 25 and 14,
respectively). LRs ranged from 0.0034 to 78.0 for moderate-priority
variants and from 0.0005 to 57.0 for patients with no flagged or
prioritized variants (Supp. Fig. S2). The proportion of LR values
supporting neutrality and those supporting causation was compa-
rable between patients with prioritized, moderately prioritized, and
flagged variants (Supp. Fig. S2). This suggests that co-segregation
analysis is only useful in the context of other supporting results for
assessing pathogenicity (e.g., likelihood of being pathogenic or be-
nign). Furthermore, the lack of genotype information and at times
smaller pedigrees likely also contributed to the lack of concordance
between LRs and variant priority.
A small number of patients with a known pathogenic variant
carried other prioritized variants. These were likely benign or pos-
sibly phenotypic modifiers. One patient possessed five prioritized
variants (one missense, one SRFBS, one TFBS, and two RBBSs) in
addition to a BRCA1 nonsense mutation (c.5503C>T). While these
variants may not directly contribute to causingHBOC, theymay act
as a risk modifier and alter expression levels [Antoniou and Easton,
2006].
Similarly, genes lacking association with HBOC can be used as a
metric for determining a false-positive rate of variant prioritization.
In this study, we prioritized 21 ATP8B1 variants among 37 of our
HBOC patients (Supp. Table S16) despite it having not been previ-
ously associated with any type of cancer. A variant with a deleterious
effect on ATP8B1may lead to ATP8B1-related diseases, such as pro-
gressive familial intrahepatic cholestasis [Gonzales et al., 2014], but
should not increase the chances of developing BC. Thus, while our
framework may be effective at prioritizing variants, only genes with
previous association to a disease should be included in analyses
similar to the present study to minimize falsely prioritized variants.
Additionalworkupof prioritized noncoding andnon-BRCA vari-
ants is particularly important, because with few exceptions [Easton
et al., 2015], the pathogenicity of many of the genes and variants
has not been firmly established. Furthermore, mutations in sev-
eral of these genes confer risk to other types of cancer, which al-
ters the management of these patients [Knappskog and Lønning,
2012]. The next step toward understanding the role these prioritized
variants play in HBOC is to test family members of the proband
and to carry out functional analysis. If this is not possible, then
their effects on gene expression could be evaluated using assays
for RNA stability and RNA localization. Protein function could be
evaluated by binding site assays, protein activity, and quantitative
PCR.
A significant challenge associated with VUS analysis, particularly
in the case ofmany of these recentHBOC gene candidates, is the un-
derreporting of variants and thus positive findings tend to be over-
represented in the literature [Kraft, 2008]. Hollestelle et al. [2010]
argue that amore stringent statistical standardmust be applied (i.e.,
P-values of 0.01 should be used as opposed to 0.05) to underre-
ported variants (namely in moderate-risk alleles), because of failure
to replicate pathogenic variants, which we have also found [Viner
et al., 2014]. In the same way that we use IT-based analysis to justify
prioritizing variants for further investigation, variants that are dis-
regarded as lower priority (and that are likely not disease causing)
have been subjected to the same thresholds and criteria. Integrating
this set of labeled prioritized and flagged, often rare variants from
this cohort of BRCA-negative HBOC patients, to findings from
exome or gene panel studies of HBOC families should accelerate the
classification of some VUS.
Different variant interpretation and reporting guidelines consider
the reporting of VUS to be either optional or essential [Wallis et al.,
2013; Richards et al., 2015]. In all cases, a reported VUS cannot
be the basis for a clinical decision and should be followed up and
further investigated. In any case, the number of reported VUS in an
individual is frequently too extensive for detailed characterization.
Reducing the full set of variants obtained by complete gene sequenc-
ing to a prioritized list will be an essential prerequisite for target-
ing potentially clinically relevant information. Informing patients
of prioritized VUS may increase patient accrual and participation
[Murphy et al., 2008]. However, it will be critical to explain both the
implications and significance of prioritization and the limitations,
namely counselling patients to avoid clinical decisions, based on this
information [Vos et al., 2012].
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